4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 85,209 | 37 | 20,723 | 3,129 | 18,038 |
| Gross Profit | 85,209 | 37 | 20,723 | 3,129 | 18,038 |
| Operating Expenses | 244,756 | 187,878 | 133,590 | 113,161 | 89,371 |
| Operating Income | -159,547 | -187,841 | -112,867 | -110,032 | -71,333 |
| Other Income | 19,438 | 26,973 | 12,030 | 2,538 | 16 |
| Pre-tax Income | -140,109 | -160,868 | -100,837 | -107,494 | -71,317 |
| Net Income Continuous | -140,109 | -160,868 | -100,837 | -107,494 | -71,317 |
| Net Income | $-140,109 | $-160,868 | $-100,837 | $-107,494 | $-71,317 |
| EPS Basic Total Ops | -2.42 | -2.98 | -2.58 | -3.32 | -2.57 |
| EPS Basic Continuous Ops | -2.42 | -2.98 | -2.58 | -3.32 | -2.57 |
| EPS Diluted Total Ops | -2.42 | -2.98 | -2.58 | -3.32 | -2.57 |
| EPS Diluted Continuous Ops | -2.42 | -2.98 | -2.58 | -3.32 | -2.57 |
| EPS Diluted Before Non-Recurring Items | N/A | -2.98 | -2.58 | -3.32 | -2.57 |
| EBITDA(a) | $-159,587 | $-190,370 | $-109,907 | $-106,570 | $-69,091 |